Market Intelligence, Polyamine Pathway Biology, and High-Purity Enzymatic Reagents for Neurological, Metabolic, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGMAT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme (WT) | AGMAT Recombinant Protein (Full Length) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Active enzyme with mitochondrial targeting sequence. |
View AGMAT Products |
| Mutant Panel | AGMAT Mutant Proteins (Cys407Ser, Arg343Ala, etc.) For mechanistic & resistance studies. Catalytic site variants. |
View AGMAT Products |
| Gene Delivery | AGMAT Lentivirus Particles / Promise-ORF Full-length ORF for stable overexpression cell lines. |
View AGMAT Products |
| Benchmark Ab | Anti-AGMAT Benchmark Antibody Recombinant positive control for target validation. |
View AGMAT Products |
| Validator | AGMAT siRNA Set For knockdown verification and pathway analysis. |
View AGMAT Products |
| Related Target A | ARG1 (Arginase 1) Critical counter-screening target; off-target toxicity control. |
View ARG1 Products |
| Related Target B | ODC1 (Ornithine Decarboxylase) Rate-limiting enzyme in polyamine synthesis; synergistic combination target. |
View ODC1 Products |
| Related Target C | SAT1 (Spermidine/Spermine N1-Acetyltransferase) Polyamine catabolism regulator; feedback bypass mechanism. |
View SAT1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Arginase Subfamily Counter-Screening (ARG1/ARG2 Off-targets) | Homolog panel proteins (AGMAT, ARG1, ARG2) strictly verified by mass spectrometry and high purity (>95%). |
| Allosteric vs. Active Site Screening | Mutant panel (Cys407Ala/Ser) for mechanistic differentiation of inhibitor binding mode. |
| Enzymatic Activity Reproducibility | HEK293 / optimized E. coli expressed proteins ensuring precise Theoretical MW and Endotoxin Controlled environments. |
| Mitochondrial Import Studies | Full-length AGMAT protein (1-353 aa) including N-terminal mitochondrial targeting sequence. |
| Pathway Cross-talk Analysis | Matched ODC1, SAT1, AMD1 recombinant proteins for polyamine flux assays. |
| Specificity Control (Knockdown) | AGMAT-specific siRNA for knockdown verification in cellular putrescine accumulation assays. |
Live AGMAT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AGMAT (agmatinase) modulators is gaining momentum as researchers uncover its critical role in polyamine metabolism, neuroprotection, and oncology. AGMAT hydrolyzes agmatine into putrescine and urea, sitting at a crucial intersection between arginine metabolism and polyamine biosynthesis. While first-generation ODC1 inhibitors (e.g., DFMO) have shown clinical utility in oncology, compensatory upregulation of AGMAT-mediated agmatine hydrolysis represents a key resistance mechanism. Current R&D focuses on small-molecule inhibitors that block the conversion of agmatine to putrescine, thereby depleting intracellular polyamine pools through non-classical routes. Beyond oncology, AGMAT inhibition also offers therapeutic potential in neuropathic pain, neuroinflammation, and psychiatric disorders by elevating endogenous agmatine, a natural NMDA receptor antagonist and NOS inhibitor. The next wave of R&D is heavily targeting highly selective inhibitors that spare related arginases (ARG1/ARG2) to prevent metabolic toxicity. Future outlook points to precision small molecules for neurodegenerative diseases and synergistic cancer therapies targeting polyamine addiction.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic & Early Biotech / Consortia | Neuropathic Pain, Neuroprotection, Solid Tumors (Colorectal, Prostate) | Selectivity Assay (high-purity AGMAT vs ARG1/ARG2); Enzymatic Activity with WT and Cys407 mutants |
| Gene Therapy / siRNA | Translational Research | Oncology (Polyamine-driven tumors) | Knockdown Validation (precise siRNA sets and benchmark Abs) |
| Biomarker Diagnostic | Clinical Dx Companies | Psychiatric Disorders, Cancer | Standardization (Endotoxin Controlled Recombinant Antigens) |
| Substrate/Metabolite Analogs | Metabolic Disorder Focused Biotech | Neuroinflammation, Hypertension | Binding Affinity (SPR/ITC) with purified AGMAT dimer |
| Combination Therapy (ODC1+AGMAT) | Oncology Pharma Partnerships | DFMO-Resistant Cancers | Pathway Panel (ODC1 + AGMAT dual protein availability) |